S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
ASX:MXC

MGC Pharmaceuticals - MXC Stock Forecast, Price & News

Add
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
2.16 million shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
MXC stock logo

About MGC Pharmaceuticals (ASX:MXC) Stock

MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. The company also provides ArtemiC range of products and cannabinoid products, as well as non-pharma products. In addition, it offers consulting services, including clinical research services. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is based in West Perth, Australia.

Receive MXC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MGC Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MXC Stock News Headlines

October 24, 2022 | proactiveinvestors.com
MGC Pharmaceuticals delivers positive Long-COVID clinical study results
October 20, 2022 | au.investing.com
MGC Pharma achieves a series of major operational and quality milestones
October 20, 2022 | au.investing.com
MGC Pharmaceuticals hits key European and US milestones
September 21, 2022 | au.investing.com
MGC Pharmaceuticals delivers encouraging results from CimetrA dose-finding study against COVID-related infections
September 21, 2022 | proactiveinvestors.com
MGC Pharma reveals encouraging early data from dosing study
September 21, 2022 | proactiveinvestors.com
MGC Pharmaceuticals delivers encouraging results from CimetrA™ dose-finding study against COVID-related infections
August 17, 2022 | marketwatch.com
MGC Pharmaceuticals Gets $1 Mln Purchase Order From U.S. Partner
August 16, 2022 | proactiveinvestors.com
MGC Pharmaceuticals secures additional ~US$1 million order for anti-inflammatory product
July 28, 2022 | proactiveinvestors.com
MGC Pharmaceuticals acquires 40% stake in ZAM Software Ltd to accelerate rollout of ZAM app
July 25, 2022 | proactiveinvestors.com
MGC Pharmaceuticals ‘confident’ as products continue progress through regulatory approval process
July 14, 2022 | proactiveinvestors.com.au
MGC Pharmaceuticals shares jump 28% after long Covid success
July 14, 2022 | proactiveinvestors.com
MGC Pharmaceuticals says ArtemiC Support can 'shorten time life of covid systems'
July 14, 2022 | proactiveinvestors.com
MGC Pharmaceuticals says ArtemiC Support can 'shorten duration of covid symptoms'
June 27, 2022 | proactiveinvestors.com
MGC Pharmaceuticals says CimetrA has wide ranging applications
June 24, 2022 | proactiveinvestors.com
MGC Pharmaceuticals finalises plans for US clinical trial of CimetrA
June 16, 2022 | proactiveinvestors.com
MGC Pharma says phase II trials show dementia drug's potential to 'inhibit deterioration in behaviour'
April 5, 2022 | proactiveinvestors.com
MGC Pharmaceuticals Ltd pens exclusive distribution agreement
April 5, 2022 | proactiveinvestors.com
MGC Pharmaceuticals agrees European distribution deal for cannabinoid treatments
February 15, 2022 | proactiveinvestors.com
MGC Pharmaceuticals present strong sales progress driven by key asset ArtemiC
January 7, 2022 | msn.com
The MGC Pharmaceuticals (ASX:MXC) share price soared 20% today. Here’s why
January 6, 2022 | proactiveinvestors.com.au
MGC Pharmaceuticals lands Indian import approval for ArtemiC Rescue product
January 6, 2022 | proactiveinvestors.com
MGC Pharmaceuticals says India approves food supplement to alleviate COVID-19 symptoms
December 22, 2021 | benzinga.com
Swiss Pharmacan's Supplement Authorized for Immediate Clinical Study to Confirm Effectiveness Against Long-COVID
December 20, 2021 | proactiveinvestors.com.au
MGC Pharmaceuticals partners begin long-Covid study using ArtemiC Support
December 8, 2021 | proactiveinvestors.com
MGC Pharmaceuticals 'in a race to get as much applications for CimetrA so we can open in 2022'
See More Headlines

Receive MXC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MGC Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MXC Company Calendar

Last Earnings
2/28/2019
Today
12/03/2022
Next Earnings (Estimated)
2/27/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
ASX
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
ASX:MXC
CUSIP
N/A
CIK
N/A
Web
www.mgcpharma.com.au
Phone
61 8 6382 3390
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
84.03
Current Ratio
0.84
Quick Ratio
0.50

Sales & Book Value

Annual Sales
$4.73 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
25.00
Book Value
A$0.00 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Roby Reuven Zomer (Age 42)
    Co-Founder, CEO, MD & Exec. Director
    Comp: $484.63k
  • Ms. Angela-Marie Graham
    Group Chief Financial Officer
  • Ms. Yifat Steuer
    Deputy CEO & COO
  • Mr. Amir Polak
    Chief Technology Officer
  • Ms. Nicole Ann Godresse
    Global Chief Sales Officer
  • Ms. Sabina Suljakovic
    Head of the Quality Assurance Department
  • Dr. Nadya Lisovoder
    Chief Medical Officer
  • Ms. Sasha Friedman
    Deputy CEO
  • Yair Tal
    Chief Information Security Officer
  • Mr. Robert Clements
    Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













MXC Stock - Frequently Asked Questions

When is MGC Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our MXC earnings forecast.

How were MGC Pharmaceuticals' earnings last quarter?

MGC Pharmaceuticals Limited (ASX:MXC) posted its earnings results on Thursday, February, 28th. The company reported $0.00 earnings per share (EPS) for the quarter.

What other stocks do shareholders of MGC Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MGC Pharmaceuticals investors own include Triton Minerals (TON), Rox Resources (RXL), Northern Minerals (NTU), Medlab Clinical (MDC), Laneway Resources (LNY), iSignthis (ISX), Intel (INTC), Bod Australia (BDA), Azure Minerals (AZS) and AusCann Group (AC8).

What is MGC Pharmaceuticals' stock symbol?

MGC Pharmaceuticals trades on the ASX under the ticker symbol "MXC."

How much money does MGC Pharmaceuticals make?

MGC Pharmaceuticals (ASX:MXC) has a market capitalization of $0.00 and generates $4.73 million in revenue each year.

How can I contact MGC Pharmaceuticals?

MGC Pharmaceuticals' mailing address is 415 W Wall St Ste 475, Midland, Texas 79701-4482. The official website for the company is www.mgcpharma.com.au. The company can be reached via phone at 61 8 6382 3390.

This page (ASX:MXC) was last updated on 12/3/2022 by MarketBeat.com Staff